Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6ZRU

Crystal structure of SARS CoV2 main protease in complex with inhibitor Boceprevir

Summary for 6ZRU
Entry DOI10.2210/pdb6zru/pdb
Related6ZRT
Related PRD IDPRD_002382
DescriptorMain Protease, DIMETHYL SULFOXIDE, boceprevir (bound form), ... (4 entities in total)
Functional Keywordsprotease, boceprevir, inhibitor, viral protein
Biological sourceSevere acute respiratory syndrome coronavirus 2
Total number of polymer chains1
Total formula weight34503.51
Authors
Oerlemans, R.,Wang, W.,Lunev, S.,Domling, A.,Groves, M.R. (deposition date: 2020-07-14, release date: 2020-08-12, Last modification date: 2024-10-16)
Primary citationOerlemans, R.,Ruiz-Moreno, A.J.,Cong, Y.,Dinesh Kumar, N.,Velasco-Velazquez, M.A.,Neochoritis, C.G.,Smith, J.,Reggiori, F.,Groves, M.R.,Domling, A.
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
Rsc Med Chem, 12:370-379, 2020
Cited by
PubMed Abstract: The rapid growth of COVID-19 cases is causing an increasing death toll and also paralyzing the world economy. drug discovery takes years to move from idea and/or pre-clinic to market, and it is not a short-term solution for the current SARS-CoV-2 pandemic. Drug repurposing is perhaps the only short-term solution, while vaccination is a middle-term solution. Here, we describe the discovery path of the HCV NS3-4A protease inhibitors boceprevir and telaprevir as SARS-CoV-2 main protease (3CLpro) inhibitors. Based on our hypothesis that α-ketoamide drugs can covalently bind to the active site cysteine of the SARS-CoV-2 3CLpro, we performed docking studies, enzyme inhibition and co-crystal structure analyses and finally established that boceprevir, but not telaprevir, inhibits replication of SARS-CoV-2 and mouse hepatitis virus (MHV), another coronavirus, in cell culture. Based on our studies, the HCV drug boceprevir deserves further attention as a repurposed drug for COVID-19 and potentially other coronaviral infections as well.
PubMed: 34041486
DOI: 10.1039/d0md00367k
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.1 Å)
Structure validation

227111

数据于2024-11-06公开中

PDB statisticsPDBj update infoContact PDBjnumon